首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIP3b |
| Uniprot No | Q99731 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-98aa |
| 氨基酸序列 | GTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRVPAVVFTTLRGRQLC APPDQPWVERIIQRLQRTSAKMKRRSS |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIP-3β(CCL19)重组蛋白的假设参考文献示例(文献内容基于领域内常见研究方向，供参考)：
---
1. **文献名称**：*Expression and functional characterization of recombinant human MIP-3β in Escherichia coli*
**作者**：Smith A, et al.
**摘要**：研究利用大肠杆菌表达系统成功制备了重组人MIP-3β蛋白，并通过体外趋化实验验证其对CCR7+ T细胞的趋化活性，为免疫调节研究提供工具。
2. **文献名称**：*MIP-3β/CCL19 enhances dendritic cell migration and antitumor immunity in a murine model*
**作者**：Li Y, et al.
**摘要**：在小鼠肿瘤模型中，重组MIP-3β通过促进树突状细胞向淋巴结迁移，增强抗原呈递和T细胞抗肿瘤反应，提示其作为肿瘤疫苗佐剂的潜力。
3. **文献名称**：*Structural analysis of CCL19/MIP-3β reveals key residues for chemokine receptor binding*
**作者**：Wang X, et al.
**摘要**：通过定点突变和晶体学分析，鉴定了MIP-3β与受体CCR7结合的关键氨基酸位点，为设计靶向免疫细胞迁移的药物提供理论依据。
---
**说明**：以上为模拟文献，实际引用请通过PubMed、Web of Science等平台检索关键词(如“MIP-3β recombinant”“CCL19 expression”“CCL19 function”)。真实文献可能聚焦于蛋白制备、免疫调控机制或疾病治疗应用。
**Background of MIP-3β Recombinant Protein**
MIP-3β (macrophage inflammatory protein-3β), also known as CCL19. is a chemokine belonging to the CC subfamily of chemokines, characterized by two adjacent cysteine residues near the N-terminus. It is primarily produced by stromal cells in lymphoid tissues, dendritic cells, and certain epithelial cells. MIP-3β plays a critical role in immune regulation by binding to the chemokine receptor CCR7. which is expressed on mature dendritic cells, naïve T cells, and regulatory T cells. This interaction facilitates the directed migration of these immune cells to secondary lymphoid organs, such as lymph nodes and the spleen, thereby promoting adaptive immune responses, T-cell activation, and lymphoid tissue organization.
The recombinant form of MIP-3β is generated using genetic engineering techniques, often expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Recombinant MIP-3β retains the functional properties of the native protein, making it a valuable tool for studying immune cell trafficking, lymphoid organ development, and CCR7-mediated signaling pathways. Its applications extend to research on inflammatory diseases, cancer immunology (e.g., tumor microenvironment studies), and autoimmune disorders, where dysregulated CCR7/CCL19 signaling is implicated.
In therapeutic contexts, MIP-3β recombinant protein has been explored for vaccine adjuvants, enhancing dendritic cell recruitment, or modulating immune tolerance. However, its dual role in both promoting anti-tumor immunity and facilitating cancer metastasis (via CCR7-dependent pathways) underscores the need for context-specific research. Overall, MIP-3β recombinant protein serves as a pivotal reagent for dissecting immune cell dynamics and developing targeted immunotherapies.
×
